BTIG Research Issues Pessimistic Forecast for DexCom (NASDAQ:DXCM) Stock Price

DexCom (NASDAQ:DXCM) had its price target reduced by stock analysts at BTIG Research from $109.00 to $85.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the medical device company’s stock. BTIG Research’s price target points to a potential upside of 46.00% from the company’s current price.

A number of other equities analysts have also recently commented on DXCM. Robert W. Baird reduced their price objective on shares of DexCom from $112.00 to $90.00 and set an “outperform” rating for the company in a research report on Friday, September 26th. Argus assumed coverage on shares of DexCom in a research report on Thursday, August 21st. They issued a “buy” rating and a $100.00 target price for the company. Canaccord Genuity Group set a $99.00 target price on shares of DexCom and gave the company a “buy” rating in a research report on Friday. Cowen reissued a “buy” rating on shares of DexCom in a research report on Friday, October 24th. Finally, Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 10th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $91.65.

DexCom Trading Down 14.6%

DXCM stock opened at $58.22 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The company has a fifty day moving average price of $70.94 and a two-hundred day moving average price of $77.96. DexCom has a one year low of $56.44 and a one year high of $93.25. The stock has a market cap of $22.83 billion, a price-to-earnings ratio of 40.43, a price-to-earnings-growth ratio of 1.43 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. During the same period in the previous year, the business posted $0.45 earnings per share. The company’s revenue for the quarter was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Equities analysts anticipate that DexCom will post 2.03 EPS for the current year.

Insiders Place Their Bets

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of the business’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the transaction, the director owned 51,121 shares of the company’s stock, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 1,466 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the transaction, the executive vice president directly owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. The trade was a 1.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 5,383 shares of company stock worth $434,274 in the last ninety days. Insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in DexCom by 1.8% during the second quarter. Vanguard Group Inc. now owns 48,322,405 shares of the medical device company’s stock worth $4,218,063,000 after acquiring an additional 866,506 shares in the last quarter. Jennison Associates LLC increased its stake in shares of DexCom by 9.4% in the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock valued at $1,005,367,000 after buying an additional 994,300 shares during the period. Geode Capital Management LLC increased its stake in shares of DexCom by 3.4% in the second quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock valued at $936,100,000 after buying an additional 358,617 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of DexCom by 22.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after buying an additional 1,868,241 shares during the period. Finally, Nuveen LLC acquired a new position in shares of DexCom in the first quarter valued at approximately $554,893,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.